Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of its Doxil cancer drug. Under JNJ's plan, existing contract manufacturer Ben Venue Labs would produce Doxil while a second supplier would handle other tasks such as ensuring the drug is sterile.